CA-MYTHICAL-GAMES
25.1.2023 13:01:43 CET | Business Wire | Press release
Mythical Games, the next-generation gaming technology studio, has launched Mythical Marketplace 2.0 following the acquisition of marketplace tech start-up DMarket, as part of its continued commitment to innovation in gaming. The new marketplace is built on Mythical’s new layer 1 EVM blockchain and powered by the Mythos native ecosystem token, MYTH. The acquisition is a significant milestone for Mythical Games, with DMarket’s tech facilitating the most advanced trading platform for digital assets. It makes Mythical the world’s second-largest processor of digital assets on a distributed ledger after the Ethereum mainnet, as of December.
Mythical’s Marketplace 2.0 has fully integrated DMarket’s technology to feature principles of its blended payment gateway, featuring a powerful AML and anti-fraud protection system built on more than a decade of industry experience. Combined with Mythical’s expertise in gaming and digital assets, Marketplace 2.0 provides a frictionless user experience that enables peer-to-peer transactions and empowerment for gamers looking to participate in the play-and-own gaming economies of the future. The Mythical Chain has been live for six weeks, processing over 2 million transactions.
“We founded Mythical Games in 2018 with the idea of ushering in both the next generation of gaming and the next generation of gamers. Half a decade later, we’re continuing to do just that. Mythical’s Marketplace 2.0 was designed to not only enhance our platform but, more importantly, improve the player experience and set the standard for the future of gaming,” said John Linden, co-founder and CEO, Mythical Games. “All too often, developers tout features as ‘seamless’ and ‘integrated’ when discussing gaming or metaverse projects. In reality, these solutions are still very complicated and not made for gamers. But with these monumental steps forward, Mythical will provide users with an experience that delivers on both.”
Marketplace 2.0 will support NFL Rivals and Nitro Nation World Tour assets, with plans to expand to all Mythical titles on the Mythical Chain. Assets on the Mythical Chain will be entirely governed by smart contracts with both ownership and commerce logic enforced on a secure distributed digital ledger.
“The new horizons of the gaming space have always been the main focus for DMarket. We’re excited to become a part of Mythical Games' work to reduce barriers to entry for innovative game developers and thriving new economies,” said Vlad Panchenko, co-founder and CEO of DMarket. “We share a vision of how the industry will evolve and how we all can contribute and bring more fun to the gaming community worldwide.”
DMarket’s office in Kyiv, Ukraine, becomes part of Mythical East, with its headquarters in Lisbon, Portugal. Its co-founders, Vlad Panchenko and Tamara Slanova, will become part of Mythical’s Executive leadership team, with a particular focus on building the best and easiest marketplace technology for the gaming industry.
DMarket has also adopted the Mythical Chain for its existing marketplace, which will continue to operate outside of the Mythical Marketplace. DMarket.com will retain the familiar experience with purchases in USD in the web experience; however, all trades are recorded on the Mythical Chain to provide full transparency to the community.
For more information on Mythical Games’ Marketplace 2.0, visit http://mythical.market.
About Mythical Platform
Mythical Platform can be added to pre-existing game economies or built into the design of a new game from the ground up, and enables management of digital asset trades, payments, users, and inventory management, making it possible for buyers and sellers of digital assets to transact confidently in an environment founded on transparency, security, trust and value. Mythical Marketplace provides seamless integration to game inventory and offers fraud protection, fee optimization, and soon asset bundling and buyer and seller pricing recommendations. Mythical partners will also have access to proprietary intelligence, market design and market intervention tools that enable easy and safe digital asset transactions.
About Mythical Games
Acknowledged by Forbes’ Disruptive Technology Companies to Watch in 2019 and Fast Company’s World Changing Ideas 2021, Mythical is a next-generation games technology company creating a gaming ecosystem by leveraging tradeable digital assets for tools that enable players, creators, artists, brands and game developers to become stakeholders and owners in new creator-focused game economies.
Led by gaming industry veterans, the team specializes in building games around player-owned economies and has helped develop major franchises, including Call of Duty, World of Warcraft, Guitar Hero, DJ Hero, Marvel Strike Force and Skylanders.
About DMarket
DMarket is the biggest marketplace for trading gaming and esports digital assets. Based on the Newzoo report, it is also one of the top three blockchain-based marketplaces worldwide. The company was founded in 2017 by serial entrepreneurs Vlad Panchenko and Tamara Slanova. DMarket's partners and customers include Darewise, GSC Game World, the Na’Vi esports team, Unity, Xsolla, and others.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230124006123/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
FPT Launches Flezi Foundry™, Advancing AI-Augmented Delivery for Global Enterprises22.5.2026 10:11:00 CEST | Press release
Global IT corporation FPT announced the launch of Flezi Foundry™ (FPT Digital Foundry™), an AI-augmented delivery platform for software development and IT operations. Built around a governed Service-as-a-Software model, the platform combines autonomous AI agents, human expert oversight, secure infrastructure, and outcome-based delivery mechanisms to help enterprises modernize technology delivery as AI agents become part of software engineering and IT operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521235556/en/ Flezi Foundry applies Agentic Engineering, a structured delivery approach for software development and IT operations. The model brings AI agents into delivery workflows with human supervision, governance, transparency, and performance measurement built into the process. Flezi Foundry operates through two service modes: Agentic Development Lifecycle (ADLC) supports software development by using specialize
Boomi Named One of The Sunday Times Best Places to Work 202622.5.2026 08:00:00 CEST | Press release
Employee-led recognition places Boomi among the UK's top medium-sized employers, with a flight risk of just 3% against a technology sector average of 42% Boomi achieves an average employee happiness score of 86%, rated Excellent across all six dimensions of WorkL's workplace framework Flight risk of just 3%, compared to a technology sector average of 42%, reflecting exceptional levels of employee loyalty Rated Excellent for Diversity and Inclusion and Confidence in Management Boomi, the data activation company for AI, has today been named one of The Sunday Times Best Places to Work 2026 in the Medium Organisation category. The prestigious annual list, produced by The Sunday Times in partnership with global workplace analytics company WorkL, recognises the UK's finest employers based entirely on direct employee feedback, making it one of the most credible and transparent employer benchmarks in the country. This press release features multimedia. View the full release here: https://www.b
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom